Trials
Search / Trial NCT05660577

Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact Lens

Launched by BAUSCH & LOMB INCORPORATED · Dec 13, 2022

Trial Information

Current as of January 22, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subjects must be age 40 years or older on the date the ICF is signed and have the capacity to provide voluntary informed consent
  • Subjects must be willing and able to comply with all treatment and follow-up/study procedures, as well as willing and able to refrain from using any contact lenses other than those provided for the duration of the study
  • Subjects must be correctable through spherocylindrical refraction to 42 letters (0.1 logMAR) or better (distance, high contrast) in each eye
  • Subjects must have clear central corneas and be free of any anterior segment disorders
  • Subject must wear their current lenses for a minimum of 12 hours per day at least four days per week
  • Subjects must habitually wear a multifocal lens in each eye
  • Subjects must be an adapted multifocal soft contact lens wearer for a minimum of 6 months
  • Subjects must require distance lens correction from +3.00 to -6.00 D in each eye
  • Subjects must be presbyopic and require near add correction from +0.75 to +2.50 D in each eye
  • Subjects must have access to an internet connection to complete an online survey and be able to receive text message
  • Exclusion Criteria:
  • Subjects participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or plan to do so during the period of study participation
  • * Subjects who are women of childbearing potential (those who are not surgically sterilized or postmenopausal) are excluded from participation in the investigation if they meet any one of the following conditions:
  • She is currently pregnant
  • She plans to become pregnant during the study
  • She is breastfeeding
  • Subjects with any systemic disease currently affecting ocular health or that, in the Investigator's opinion, may have an effect on ocular health during the course of the study
  • Subjects with an active ocular disease
  • Subjects who have had any corneal surgery (e.g., refractive surgery)
  • Subjects who have worn gas-permeable (GP) contact lenses within the last 30 days or who have worn polymethylmethacrylate (PMMA) lenses within the last 3 months
  • Subjects who currently wear monovision or toric contact lenses
  • Subjects who are not correctable to 32 letters (0.3 logMAR) with bilateral soft multifocal contact lenses
  • Subjects with an ocular astigmatism \>1.00 D in either eye
  • Subjects with anisometropia (spherical equivalent) \>2.00 D
  • Subjects with any Grade ≥2 finding during the slit lamp examination. Subjects with corneal infiltrates of ANY GRADE are not eligible
  • Any "Present" finding during the slit lamp examination that, in the Investigator's opinion, interferes with contact lens wear
  • Any scar or neovascularization within the central 6 mm of the cornea. Subjects with minor peripheral corneal scarring (that does not extend into the central area) that, in the Investigator's opinion, does not interfere with contact lens wear are eligible for this study
  • Subjects who are amblyopic
  • Subjects using any systemic or topical ocular medication that will, in the Investigator's opinion, affect ocular physiology or lens performance
  • Subjects who are allergic to any component in the study care products

About Bausch & Lomb Incorporated

Bausch & Lomb Incorporated is a leading global eye health company dedicated to advancing the vision and well-being of individuals through innovative products and solutions. With a rich history spanning over 160 years, Bausch & Lomb specializes in the development, manufacturing, and marketing of a comprehensive range of eye care products, including contact lenses, lens care solutions, and pharmaceuticals for various ocular conditions. The company is committed to rigorous clinical research and trials to ensure the safety and efficacy of its offerings, striving to enhance patient outcomes and improve quality of life for those with vision-related challenges.

Locations

Memphis, Tennessee, United States

Warwick, Rhode Island, United States

Pittsburg, Kansas, United States

Raleigh, North Carolina, United States

Orlando, Florida, United States

Jamestown, New York, United States

Edina, Minnesota, United States

Sarasota, Florida, United States

Orlando, Florida, United States

Shelby, North Carolina, United States

San Diego, California, United States

San Francisco, California, United States

Denver, Colorado, United States

Jacksonville, Florida, United States

Decatur, Georgia, United States

Leavenworth, Kansas, United States

Portland, Maine, United States

Saint Louis, Missouri, United States

Vestal, New York, United States

Nashville, Tennessee, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials